Total revenue for the fourth quarter of 2005 was $22.4 million compared to $20.1 million for the fourth quarter of 2004, an increase of $2.4 million or 12%. Genomics Services revenue increased $3.7 million, or 27%, over the prior year period, and included $6.9 million from the sale to several existing customers of perpetual licenses for certain data and software, and reflects the Company's broadening of its Genomics Services offerings. Nonclinical Services revenue decreased $1.6 million or 26% reflecting continued business development and capacity utilization challenges. Drug Repositioning and Selection Partnerships ("DRS Business") recorded a small amount of revenue.
